The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE - MyChesCo
KING OF PRUSSIA, PA — Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), announced that The Lancet recently published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as …
MyChesCo
